Clinical Trial Update: A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating errors, training time, and preferences for the ELLIPTA Dry Powder Inhaler compared with other DPIs for triple therapy in COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ELLIPTA Dry Powder Inhaler

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2019-10-21